The smart way to treat dry eye

Article

Insertion of a SmartPlug (Medennium) can be an effective management tool for severe dry eye syndrome.

Insertion of a SmartPlug (Medennium) can be an effective management tool for severe dry eye syndrome, according to a report published in the June issue of Cornea.

Simon Chen and Graham Lee of the University of Queensland, Australia conducted a retrospective chart review of patients undergoing SmartPlug insertion between June 2003 and December 2005.

A total of 91 eyes of 54 patients (44 women and 10 men) were included in the review. The average follow-up period was 13.0±6.0 months, with a minimum of six months. Thirty patients (60.4%) reported using a decreased amount of lubricant eye drops, including nine patients (15.4%) who were altogether free of eye drop use. Forty-one patients (75.8%) reported subjective symptom improvement after insertion of the SmartPlug. Meanwhile, complications included canaliculitis (6.6%), epiphora requiring plug removal (5.5%) and spontaneous plug loss (2.2%).

The study demonstrates that the SmartPlug can be useful in treating severe dry eye but the authors warn that long-term follow-up is required for potentially serious complications such as canaliculitis.

The SmartPlug is available throughout Europe and the US, as well as other countries around the world.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.